Inhibikase Therapeutics, Inc. - ROE

The ROE as of June 2026 (TTM) for Inhibikase Therapeutics, Inc. (IKT) is -41.31%

According to Inhibikase Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -41.31%. This represents a change of 260.07% compared to the average of -11.47% of the last 4 quarters.

Inhibikase Therapeutics, Inc. (IKT) Historical ROE (quarterly & annually)

How has IKT ROE performed in the past?

The mean historical ROE of Inhibikase Therapeutics, Inc. over the last ten years is 9.72%. The current -41.31% ROE has changed -524.84% with respect to the historical average. Over the past ten years (40 quarters), IKT's ROE was at its highest in in the September 2024 quarter at 1.09%. The ROE was at its lowest in in the June 2024 quarter at -97.31%.

Inhibikase Therapeutics, Inc. (IKT) ROE by Quarter and Year

Discovering the peaks and valleys of Inhibikase Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Inhibikase Therapeutics, Inc. (IKT) Average ROE

How has IKT ROE performed in the past?

The current ROE of Inhibikase Therapeutics, Inc. (IKT) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

Inhibikase Therapeutics, Inc. (IKT) ROE vs. Peers

How is IKT’s ROE compared to its peers?

Inhibikase Therapeutics, Inc.’s ROE is greater than Turn Therapeutics Inc. (-116.83%), greater than Cognition Therapeutics, Inc. (-72.68%), less than Surrozen, Inc. (309.79%), less than Tevogen Bio Holdings Inc. (241.39%), greater than Greenwich LifeSciences, Inc. (-814.48%), greater than eXoZymes, Inc. (-220.64%), less than Estrella Immunopharma, Inc. (167.91%), greater than Atossa Therapeutics, Inc. (-84.91%), greater than Agenus Inc. (-23.05%), greater than Entera Bio Ltd. (-87.97%),

Build a custom stock screener for Inhibikase Therapeutics, Inc. (IKT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Inhibikase Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Inhibikase Therapeutics, Inc. (IKT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Inhibikase Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.